{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:26Z","timestamp":1793210906314,"version":"4.5.0"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jns.2025.125659","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:43:42Z","timestamp":1763639022000},"page":"125659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Autoimmune neuropathies: New guidelines and expert insights into clinical decision making"],"prefix":"10.1016","volume":"479","author":[{"given":"Pieter A.","family":"van Doorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf A.","family":"Rajabally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0005","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barre syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0010","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"10045","key":"10.1016\/j.jns.2025.125659_bb0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"9497","key":"10.1016\/j.jns.2025.125659_bb0030","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"Pt 1","key":"10.1016\/j.jns.2025.125659_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0045","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barre syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"issue":"Suppl","key":"10.1016\/j.jns.2025.125659_bb0050","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/practneurol-2014-000937","article-title":"Mimics and chameleons in Guillain-Barre and Miller Fisher syndromes","volume":"15","author":"Wakerley","year":"2015","journal-title":"Pract. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1469-0691.2006.01636.x","article-title":"Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barre syndrome: a single Centre prospective case-control study","volume":"13","author":"Sinha","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jnnp.51.5.613","article-title":"A prospective study of acute idiopathic neuropathy. II. Antecedent events","volume":"51","author":"Winer","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb0080","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1468-1331.2006.01390.x","article-title":"A case-control study of Guillain-Barre syndrome in Harbin, China","volume":"13","author":"Cheng","year":"2006","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0085","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0895-4356(94)90108-2","article-title":"A case-control study of drugs and other determinants as potential causes of Guillain-Barr\u00e9 syndrome","volume":"47","author":"Stricker","year":"1994","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barre syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"Tam","year":"2007","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barr\u00e9 syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am. J. Epidemiol."},{"issue":"31","key":"10.1016\/j.jns.2025.125659_bb0110","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barre syndrome and influenza vaccines: a meta-analysis","volume":"33","author":"Martin Arias","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barre syndrome following recombinant zoster vaccine in Medicare beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0120","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0125","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/brain\/awac067","article-title":"COVID-19 vaccination and Guillain-Barre syndrome: analyses using the National Immunoglobulin Database","volume":"146","author":"Keh","year":"2023","journal-title":"Brain"},{"issue":"16","key":"10.1016\/j.jns.2025.125659_bb0130","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of Receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barre syndrome, February-July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"issue":"37","key":"10.1016\/j.jns.2025.125659_bb0135","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","article-title":"Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome","volume":"37","author":"Principi","year":"2019","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.jns.2025.125659_bb0140","doi-asserted-by":"crossref","first-page":"e1220","DOI":"10.1212\/WNL.0000000000006246","article-title":"Surgery and risk of Guillain-Barre syndrome: a French nationwide epidemiologic study","volume":"91","author":"Rudant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.125659_bb0145","article-title":"Guillain-Barre syndrome after surgery: a literature review","volume":"15","author":"Li","year":"2024","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0150","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1111\/ene.15955","article-title":"Hospital-diagnosed morbidities and recent surgery as risk factors for developing Guillain-Barre syndrome","volume":"30","author":"Levison","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"23","key":"10.1016\/j.jns.2025.125659_bb0155","doi-asserted-by":"crossref","first-page":"e2386","DOI":"10.1212\/WNL.0000000000207282","article-title":"CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barre Syndrome","volume":"100","author":"Al-Hakem","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0160","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mus.24226","article-title":"Sural sparing pattern discriminates Guillain-Barre syndrome from its mimics","volume":"50","author":"Derksen","year":"2014","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mus.20532","article-title":"Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed distal compound muscle action potential to electrodiagnosis","volume":"33","author":"Cleland","year":"2006","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neucli.2015.12.008","article-title":"Diagnostic accuracy of neurophysiological criteria for early diagnosis of AIDP: a prospective study","volume":"46","author":"Scarpino","year":"2016","journal-title":"Neurophysiol. Clin."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20342","article-title":"New criteria for early electrodiagnosis of acute inflammatory demyelinating polyneuropathy","volume":"32","author":"Al-Shekhlee","year":"2005","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0180","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.58.6.913","article-title":"Early electrodiagnostic findings in Guillain-Barr\u00e9 syndrome","volume":"58","author":"Gordon","year":"2001","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0185","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.clinph.2004.05.009","article-title":"Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy","volume":"115","author":"Vucic","year":"2004","journal-title":"Clin. Neurophysiol."},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb0190","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinph.2014.01.007","article-title":"Early electrodiagnostic abnormalities in acute inflammatory demyelinating polyneuropathy: a retrospective study of 58 patients","volume":"125","author":"Chanson","year":"2014","journal-title":"Clin. Neurophysiol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-009-5386-x","article-title":"Motor-dominant chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Kimura","year":"2010","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1529-8027.2011.00338.x","article-title":"Very early electrodiagnostic findings in Guillain-Barre syndrome","volume":"16","author":"Alberti","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0205","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.clinph.2015.01.016","article-title":"Sural-sparing is seen in axonal as well as demyelinating forms of Guillain-Barre syndrome","volume":"126","author":"Umapathi","year":"2015","journal-title":"Clin. Neurophysiol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000069416","article-title":"Indirect discharges as an early nerve conduction abnormality in the Guillain-Barr\u00e9 syndrome","volume":"42","author":"Roth","year":"1999","journal-title":"Eur. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0215","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1468-1331.2011.03365.x","article-title":"Measurement of motor root conduction time at the early stage of Guillain-Barre syndrome","volume":"18","author":"Temucin","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0220","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/mus.21974","article-title":"Value of distal compound muscle action potential duration prolongation in acute inflammatory demyelinating polyneuropathy: a European perspective","volume":"43","author":"Rajabally","year":"2011","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125659_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000347224","article-title":"Sensory conduction study in fisher syndrome: patterns of abnormalities and their clinical correlation","volume":"70","author":"Lyu","year":"2013","journal-title":"Eur. Neurol."},{"issue":"5\u20136","key":"10.1016\/j.jns.2025.125659_bb0230","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000353286","article-title":"Motor conduction findings in Fisher syndrome","volume":"70","author":"Lyu","year":"2013","journal-title":"Eur. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0235","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1038\/s41598-019-44090-w","article-title":"Graded, Electrodiagnostic criterion for Guillain-Barre syndrome that incorporates sensory nerve conduction studies","volume":"9","author":"Umapathi","year":"2019","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125659_bb0240","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0165-5728(98)00182-9","article-title":"Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barr\u00e9 syndrome and other demyelinating polyneuropathies","volume":"91","author":"Pestronk","year":"1998","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0245","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","article-title":"Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies","volume":"124","author":"Uncini","year":"2013","journal-title":"Clin. Neurophysiol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ana.410440210","article-title":"IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barr\u00e9 syndrome","volume":"44","author":"Kuwabara","year":"1998","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0255","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac306","article-title":"Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model","volume":"4","author":"Campbell","year":"2022","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000355830","article-title":"Evaluating the status of antiganglioside antibodies in children with Guillain-Barre syndrome","volume":"21","author":"Hashemilar","year":"2014","journal-title":"Neuroimmunomodulation"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0265","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1089\/fpd.2009.0493","article-title":"Association study between an outbreak of Guillain-Barre syndrome in Jilin, China, and preceding Campylobacter jejuni infection","volume":"7","author":"Zhang","year":"2010","journal-title":"Foodborne Pathog. Dis."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0270","first-page":"111","article-title":"Antibodies to gangliosides in Guillain-Barr\u00e9 syndrome: specificity and relationship to clinical features","volume":"86","author":"Gregson","year":"1993","journal-title":"Q. J. Med."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0275","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0280","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-510X(93)90048-4","article-title":"Serum and CSF anti-GM1 antibodies in patients with Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"114","author":"Simone","year":"1993","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0285","first-page":"379","article-title":"Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a","volume":"5","author":"Mat\u00e0","year":"1999","journal-title":"Mult. Scler."},{"issue":"Pt 3","key":"10.1016\/j.jns.2025.125659_bb0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/brain\/118.3.597","article-title":"Guillain-Barr\u00e9 syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies","volume":"118","author":"Ho","year":"1995","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0295","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","article-title":"Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh","volume":"74","author":"Islam","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0300","first-page":"322","article-title":"Clinical relevance of the determination of anti-GQ1b antibodies in Miller Fisher and Guillain-Barr\u00e9 syndromes","volume":"98","author":"Goffette","year":"1998","journal-title":"Acta Neurol. Belg."},{"issue":"19","key":"10.1016\/j.jns.2025.125659_bb0305","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0000000000002558","article-title":"Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes","volume":"86","author":"Spatola","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0022-510X(97)00312-2","article-title":"Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy","volume":"155","author":"Carpo","year":"1998","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0315","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.410310619","article-title":"Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome","volume":"31","author":"Chiba","year":"1992","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp-2013-305397","article-title":"Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome","volume":"85","author":"Wakerley","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"22","key":"10.1016\/j.jns.2025.125659_bb0325","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/WNL.0000000000000481","article-title":"Paraparetic Guillain-Barr\u00e9 syndrome","volume":"82","author":"van den Berg","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0330","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-008-0775-0","article-title":"Bickerstaff\u2019s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases","volume":"255","author":"Ito","year":"2008","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125659_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.05.020","article-title":"Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome)","volume":"215","author":"Yuki","year":"2009","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0340","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp-2022-329937","article-title":"Modified Erasmus GBS respiratory insufficiency score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barre syndrome","volume":"94","author":"Luijten","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0345","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0350","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/cir074","article-title":"Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study","volume":"52","author":"Orlikowski","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0355","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/ane.13294","article-title":"A nomogram to predict mechanical ventilation in Guillain-Barr\u00e9 syndrome patients","volume":"142","author":"Ning","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcrc.2013.10.026","article-title":"Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome","volume":"29","author":"Kannan Kanikannan","year":"2014","journal-title":"J. Crit. Care"},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0365","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(06)70603-2","article-title":"Clinical and electrophysiological predictors of respiratory failure in Guillain-Barr\u00e9 syndrome: a prospective study","volume":"5","author":"Durand","year":"2006","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0370","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pr.2017.67","article-title":"Predictive factors for achieving independent walking in children with Guillain-Barre syndrome","volume":"82","author":"Barzegar","year":"2017","journal-title":"Pediatr. Res."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0375","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00415-012-6806-x","article-title":"Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation","volume":"260","author":"Witsch","year":"2013","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0380","first-page":"670","article-title":"Guillain Barre syndrome-electrodiagnostic features and therapeutic observations","volume":"43","author":"Shankar","year":"1995","journal-title":"J. Assoc. Physicians India"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jns5.12050","article-title":"Guillain-Barr\u00e9 syndrome: subtypes and predictors of outcome from India","volume":"19","author":"Kalita","year":"2014","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0390","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/WNL.48.1.214","article-title":"A prospective study on the incidence and prognosis of Guillain-Barr\u00e9 syndrome in Emilia-Romagna region, Italy (1992\u20131993). Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology","volume":"48","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0395","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.410230406","article-title":"Plasmapheresis and Guillain-Barr\u00e9 syndrome: analysis of prognostic factors and the effect of plasmapheresis","volume":"23","author":"McKhann","year":"1988","journal-title":"Ann. Neurol."},{"issue":"Pt 6","key":"10.1016\/j.jns.2025.125659_bb0400","first-page":"2053","article-title":"The prognosis and main prognostic indicators of Guillain-Barr\u00e9 syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barr\u00e9 Study Group","volume":"119","year":"1996","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0405","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors, and outcome in Guillain-Barr\u00e9 syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0410","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0415","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.53.3.598","article-title":"Prognostic factors of Guillain-Barr\u00e9 syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barr\u00e9 Study Group","volume":"53","author":"Visser","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0420","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barre syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.125659_bb0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jns.2013.09.002","article-title":"Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS)","volume":"335","author":"Verma","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0430","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0435","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","article-title":"Predicting outcome in Guillain-Barre Syndrome: international validation of the modified erasmus GBS outcome score","volume":"98","author":"Doets","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0440","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/acn3.307","article-title":"Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS","volume":"3","author":"Fokkink","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barre syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2025.125659_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105072","article-title":"Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barre syndrome","volume":"102","author":"van Tilburg","year":"2024","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0455","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp-2025-336046","article-title":"Neurofilament light chain improves clinical prognostic models for Guillain-Barre syndrome","volume":"96","author":"Thomma","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0460","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200419","article-title":"Serum Neurofilament light chain as a biomarker for CIDP diagnosis, severity, and treatment outcome","volume":"12","author":"Klimas","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2025.125659_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123397","article-title":"Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"470","author":"Llaurado","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0470","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0475","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0480","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome. The Guillain-Barr\u00e9 syndrome Study Group","volume":"35","year":"1985","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0485","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 syndrome","volume":"22","year":"1987","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0490","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome. The French cooperative group on plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"41","year":"1997","journal-title":"Ann. Neurol."},{"issue":"17","key":"10.1016\/j.jns.2025.125659_bb0495","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"9047","key":"10.1016\/j.jns.2025.125659_bb0500","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0505","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0510","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0515","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit. Care"},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb0520","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8093","key":"10.1016\/j.jns.2025.125659_bb0525","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0530","article-title":"Corticosteroids for Guillain-Barre syndrome","volume":"10","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8845","key":"10.1016\/j.jns.2025.125659_bb0535","first-page":"586","article-title":"Double-blind trial of intravenous methylprednisolone in Guillain-Barr\u00e9 syndrome. Guillain-Barr\u00e9 syndrome steroid trial group","volume":"341","year":"1993","journal-title":"Lancet"},{"issue":"9404","key":"10.1016\/j.jns.2025.125659_bb0540","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0545","first-page":"22","article-title":"Do corticosteroids influence the disease course or mortality in Guillain-Barre\u2019 syndrome?","volume":"44","author":"Singh","year":"1996","journal-title":"J. Assoc. Physicians India"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0550","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0555","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","article-title":"Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange","volume":"54","author":"Kleyweg","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Pt 9","key":"10.1016\/j.jns.2025.125659_bb0560","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barre syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.125659_bb0565","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3389\/fimmu.2018.01029","article-title":"Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance","volume":"9","author":"Vural","year":"2018","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.jns.2025.125659_bb0570","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.125659_bb0575","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-12-802973-2.00015-X","article-title":"Peripheral neuropathies","volume":"138","author":"Hanewinckel","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0580","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/mus.10361","article-title":"Phrenic nerve palsy as a feature of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"27","author":"Stojkovic","year":"2003","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0585","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00415-005-0848-2","article-title":"Chronic inflammatory demyelinating polyneuropathy and respiratory failure","volume":"252","author":"Henderson","year":"2005","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0590","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.50.4.1179","article-title":"Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy","volume":"50","author":"Sakakibara","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0595","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mus.20140","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement","volume":"31","author":"Yamamoto","year":"2005","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0600","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mus.20438","article-title":"Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"33","author":"Stamboulis","year":"2006","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0605","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/jnnp.2009.179358","article-title":"Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study","volume":"80","author":"Rajabally","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0610","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.21199","article-title":"Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features","volume":"39","author":"Rajabally","year":"2009","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0615","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","article-title":"Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies","volume":"88","author":"Koike","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0620","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.23794","article-title":"Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy","volume":"73","author":"Querol","year":"2013","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0625","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0630","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2014-309916","article-title":"Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies","volume":"86","author":"Doppler","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0635","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/acn3.248","article-title":"Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy","volume":"2","author":"Ogata","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb0640","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0645","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/ene.13380","article-title":"A comparative study of brachial plexus sonography and magnetic resonance imaging in chronic inflammatory demyelinating neuropathy and multifocal motor neuropathy","volume":"24","author":"Goedee","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0650","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.0000000000003483","article-title":"Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies","volume":"88","author":"Goedee","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0655","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00415-016-8305-y","article-title":"Peripheral nerve ultrasound scoring systems: benchmarking and comparative analysis","volume":"264","author":"Grimm","year":"2017","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0660","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s00415-013-7123-8","article-title":"Ultrasound of inherited vs. acquired demyelinating polyneuropathies","volume":"260","author":"Zaidman","year":"2013","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0665","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1212\/WNL.47.1.98","article-title":"Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up","volume":"47","author":"Nevo","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2025.125659_bb0670","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1569::AID-MUS12>3.0.CO;2-W","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults","volume":"20","author":"Simmons","year":"1997","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0675","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0960-8966(00)00119-X","article-title":"Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome","volume":"10","author":"Ryan","year":"2000","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0680","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(00)00493-7","article-title":"Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy","volume":"184","author":"Hattori","year":"2001","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0685","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0002-9343(94)90173-2","article-title":"Age and sex associations of 40 autoimmune diseases","volume":"96","author":"Beeson","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jns.2025.125659_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1038411","article-title":"Sex differences in Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis","volume":"13","author":"McCombe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2025.125659_bb0695","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-4933-7-4","article-title":"The effect of ageing on human lymphocyte subsets: comparison of males and females","volume":"7","author":"Yan","year":"2010","journal-title":"Immun. Ageing"},{"issue":"18","key":"10.1016\/j.jns.2025.125659_bb0700","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","article-title":"Prevalence of polyneuropathy in the general middle-aged and elderly population","volume":"87","author":"Hanewinckel","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0705","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/jns.12502","article-title":"Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in the Netherlands","volume":"27","author":"Broers","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0710","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jdiacomp.2016.05.007","article-title":"The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy","volume":"30","author":"Bril","year":"2016","journal-title":"J. Diabetes Complicat."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0715","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/jnnp-2020-322971","article-title":"Chronic inflammatory demyelinating polyneuropathy associated with diabetes: a European multicentre comparative reappraisal","volume":"91","author":"Rajabally","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0720","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.WNL.0000096174.86850.7F","article-title":"Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP","volume":"61","author":"Jann","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0725","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ene.14044","article-title":"Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database","volume":"27","author":"Doneddu","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0730","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.27374","article-title":"Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study","volume":"64","author":"Rajabally","year":"2021","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0735","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2010.03312.x","article-title":"Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases","volume":"18","author":"Larue","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0740","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.61.1.36","article-title":"Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients","volume":"61","author":"Maisonobe","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb0745","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2025.125659_bb0750","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1007\/s10875-014-0026-3","article-title":"MMN: from immunological cross-talk to conduction block","volume":"34 Suppl 1","author":"Harschnitz","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0755","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(13)70236-9","article-title":"Vasculitic neuropathies","volume":"13","author":"Gwathmey","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0760","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0765","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A vasculitis Centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0770","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1346-8138.2011.01316.x","article-title":"Elderly cases of Churg-Strauss syndrome: case report and review of Japanese cases","volume":"39","author":"Uchiyama","year":"2012","journal-title":"J. Dermatol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0775","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11910-023-01249-3","article-title":"Central and peripheral nervous system complications of Vasculitis syndromes from pathology to bedside: part 2-peripheral nervous system","volume":"23","author":"Mansueto","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0780","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/WCO.0000000000000727","article-title":"Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies","volume":"32","author":"Collins","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2025.125659_bb0785","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1093\/rheumatology\/keaa075","article-title":"Vasculitis and the peripheral nervous system","volume":"59","author":"Ginsberg","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0790","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1529-8027.2010.00281.x","article-title":"Peripheral nerve society guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary","volume":"15","author":"Collins","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0795","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200365","article-title":"The discovery of autoimmune Nodopathies and the impact of IgG4 antibodies in autoimmune neurology","volume":"12","author":"Querol","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0800","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.125659_bb0805","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1475478","article-title":"Case report: target antigen and subclass switch in a patient with autoimmune nodopathy","volume":"15","author":"Appeltshauser","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb0810","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"Pt 6","key":"10.1016\/j.jns.2025.125659_bb0815","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Miura","year":"2015","journal-title":"Brain"},{"issue":"Pt 10","key":"10.1016\/j.jns.2025.125659_bb0820","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/brain\/aww189","article-title":"Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0825","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0830","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/awab014","article-title":"Antibodies to the Caspr1\/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"144","author":"Pascual-Goni","year":"2021","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0835","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0840","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0845","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001163","article-title":"Diabetes mellitus is a possible risk factor for Nodo-paranodopathy with Antiparanodal autoantibodies","volume":"9","author":"Appeltshauser","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0850","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/clc.23434","article-title":"Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy","volume":"43","author":"Teng","year":"2020","journal-title":"Clin. Cardiol."},{"issue":"21","key":"10.1016\/j.jns.2025.125659_bb0855","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0860","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2025.125659_bb0865","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/WCO.0000000000000735","article-title":"Charcot\u2013Marie\u2013tooth disease and related disorders: an evolving landscape","volume":"32","author":"Laur\u00e1","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2025.125659_bb0870","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/jnnp.2009.194324","article-title":"Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance","volume":"81","author":"Merkies","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0875","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0880","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the overall neuropathy limitations scale","volume":"77","author":"Graham","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0885","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0890","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0895","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mus.26747","article-title":"Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Rajabally","year":"2020","journal-title":"Muscle Nerve"},{"issue":"23","key":"10.1016\/j.jns.2025.125659_bb0905","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mus.27250","article-title":"Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Rajabally","year":"2021","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/jns.12487","article-title":"Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy","volume":"27","author":"Merkies","year":"2022","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jns.2025.125659_bb0920","author":"M.R. Council"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0925","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb0930","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neurol."},{"issue":"14","key":"10.1016\/j.jns.2025.125659_bb0935","doi-asserted-by":"crossref","first-page":"e1876","DOI":"10.1212\/WNL.0000000000011703","article-title":"Quantifying treatment-related fluctuations in CIDP: results of the GRIPPER study","volume":"96","author":"Allen","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0940","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0945","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and safety of Privigen((R)) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label phase III study (the PRIMA study)","volume":"18","author":"Leger","year":"2013","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb0950","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/jns.12408","article-title":"An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study","volume":"25","author":"Nobile-Orazio","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb0955","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00415-018-9157-4","article-title":"Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy","volume":"266","author":"Rajabally","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2025.125659_bb0960","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0965","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating Polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"Pt 4","key":"10.1016\/j.jns.2025.125659_bb0970","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb0975","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2015","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb0980","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.transci.2016.01.003","article-title":"Adverse events in apheresis: an update of the WAA registry data","volume":"54","author":"Mortzell Henriksson","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.jns.2025.125659_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120478","article-title":"Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"443","author":"Lewis","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb0990","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb0995","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb1000","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/jnnp-2013-306105","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal","volume":"85","author":"Rabin","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb1005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2014-308452","article-title":"Different electrophysiological profiles and treatment response in \u2018typical\u2019 and \u2018atypical\u2019 chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Kuwabara","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2025.125659_bb1010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","article-title":"Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database","volume":"90","author":"Doneddu","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb1015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.21206","article-title":"Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population","volume":"39","author":"Rajabally","year":"2009","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.jns.2025.125659_bb1020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","article-title":"Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin","volume":"57","author":"Donaghy","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb1025","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s004150170093","article-title":"Pure motor chronic inflammatory demyelinating polyneuropathy","volume":"248","author":"Sabatelli","year":"2001","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2025.125659_bb1030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2377-14-72","article-title":"Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern","volume":"14","author":"Eftimov","year":"2014","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb1035","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00415-008-0687-z","article-title":"Electrophysiological predictors of steroid-responsiveness in chronic inflammatory demyelinating polyneuropathy","volume":"255","author":"Rajabally","year":"2008","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb1040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/mus.25271","article-title":"Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy","volume":"55","author":"Kaplan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb1045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/00207454.2016.1269328","article-title":"A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients","volume":"127","author":"Debs","year":"2017","journal-title":"Int. J. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2025.125659_bb1050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/ene.14096","article-title":"Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study","volume":"27","author":"Adrichem","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.125659_bb1055","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1212\/WNL.51.6.1735","article-title":"Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Good","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2025.125659_bb1060","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/jnnp-2023-332844","article-title":"Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies","volume":"95","author":"Doneddu","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2025.125659_bb1065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2024","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jns.2025.125659_bb1070","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/ene.15857","article-title":"Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.125659_bb1085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2025.125659_bb1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123313","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","volume":"468","author":"Levine","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2025.125659_bb1105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","article-title":"Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study","volume":"95","author":"Querol","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7_supplement_1","key":"10.1016\/j.jns.2025.125659_bb1120","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000204596","article-title":"Preliminary efficacy and safety data from the Phase 2 Trial of Riliprubart (SAR445088), a humanized monoclonal antibody targeting complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008)","volume":"102","author":"Querol","year":"2024","journal-title":"Neurology"},{"issue":"7_Supplement_1","key":"10.1016\/j.jns.2025.125659_bb1125","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210365","article-title":"Phase 2 efficacy and safety of Riliprubart, a C1s-complement inhibitor, in chronic inflammatory demyelinating polyneuropathy (S16.009)","volume":"104","author":"Querol","year":"2025","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2025.125659_bb1140","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70009","article-title":"Results from a phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ANX005, a C1q inhibitor, in patients with Guillain-Barre syndrome","volume":"30","author":"Mohammad","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"7_Supplement_1","key":"10.1016\/j.jns.2025.125659_bb1145","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000212033","article-title":"Efficacy and safety of targeted immunotherapy with ANX005 in treating Guillain-Barr\u00e9 syndrome: a phase 3 multicenter study (PL5.006)","volume":"104","author":"Kroon","year":"2025","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25022798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25022798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:23:28Z","timestamp":1765412608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25022798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":219,"alternative-id":["S0022510X25022798"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125659","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune neuropathies: New guidelines and expert insights into clinical decision making","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125659"}}